Clinical Trials Logo

Hormone Antagonist clinical trials

View clinical trials related to Hormone Antagonist.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02997995 Completed - Breast Cancer Clinical Trials

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

ULTIMATE
Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor). The trial includes two sequences: The first part of the treatment will consist in 4-6 weeks treatment with immune-attractants; in the second part, CD8+ patients will receive 6 months of durvalumab combined with exemestane.